πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 405 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12220389

Combination therapy for the treatment of tinnitus and other medical conditions

The Regents of the University of California Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12208099

Combination therapies

Mirati Therapeutics, Inc. Β· Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12201719

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

VACCINEX, INC. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12186428

Combination taxoid nanoemulsion with immunotherapy in cancer

Northwestern University Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12171765

Combination therapies using PRMT5 inhibitors for the treatment of cancer

Mirati Therapeutics, Inc. Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12168054

Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody

Syndax Pharmaceuticals, Inc. Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161607

Combination of cannabinoids in the treatment of leukemia

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156863

Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

Galera Labs, LLC Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144813

PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

Cardiff Oncology, Inc. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128034

Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof

Iterum Therapeutics International Limited Β· Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128048

Combination therapies using PRMT5 inhibitors for the treatment of cancer

Mirati Therapeutics, Inc. Β· Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121288

Combination tumor treatment

Regents of the University of Minnesota Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12115163

Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor

IDEAYA Biosciences, Inc. Β· Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109258

Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat mal

Inovio Pharmaceuticals, Inc. Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109197

Combinations of Ξ²-lactam compounds and probenecid and uses thereof

Iterum Therapeutics International Limited Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12102617

Antimicrobial compositions containing a synergistic combination of activated creatinine an

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12090183

Methods of treating solid or lymphatic tumors by combination therapy

CG ONCOLOGY, INC. Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12090145

Combination therapy for treating or preventing depression or other mood diseases

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091460

Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12090142

Combination therapy for the treatment of cancer

The Board of Regents of the University of Texas System Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084516

Anti-C5 antibody combinations and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12077785

Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modu

SOTIO BIOTECH INC. Β· Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12076324

Cancer treatments using combinations of CDK and ERK inhibitors

Biomed Valley Discoveries, Inc. Β· Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12076409

Polymer-drug conjugates for combination anticancer therapy

The Regents of the University of California Β· Granted Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted